Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Employees - 71880,
CEO - Mr. Lars Fruergaard Jorgensen,
Sector - Healthcare,
Country - DK,
Market Cap - 283.77B
Altman ZScore(max is 10): 3.1, Piotroski Score(max is 10): 7, Working Capital: $-13198000000, Total Assets: $397441000000, Retained Earnings: $121670000000, EBIT: 124772000000, Total Liabilities: $276919000000, Revenue: $270583000000
AryaFin Target Price - $136.17 - Current Price $85.00 - Analyst Target Price $131.93
| Ticker | NVO |
| Index | - |
| Curent Price | 85.00 |
| Change | -17.83% |
| Market Cap | 283.77B |
| Average Volume | 6.08M |
| Income | 13.78B |
| Sales | 39.33B |
| Book Value/Share | 5.40 |
| Cash/Share | 3.36 |
| Dividend Est | 1.56 (1.83%) |
| Dividend TTM | 1.45 (1.70%) |
| Dividend Ex-Date | Aug 16, 2024 |
| Employees | 63370 |
| Moving Avg 20days | -20.30% |
| Moving Avg 50days | -22.22% |
| Moving Avg 200days | -32.67% |
| Shares Outstanding | 3.34B |
| Earnings Date | Nov 06 BMO |
| Inst. Ownership | 9.99% |
| Price/Earnings | 27.56 |
| Forwad P/E | 21.40 |
| PE Growth | 2.51 |
| Price/Sales | 7.21 |
| Price/Book | 15.73 |
| Price/Cash | 25.31 |
| Price/FCF | 25.04 |
| Quick Ratio | 0.75 |
| Current Ratio | 0.94 |
| Debt/Equity | 0.47 |
| Return on Assets | 26.99% |
| Return on Equity | 88.20% |
| Return on Investment | 53.52% |
| Gross Margin | 84.66% |
| Ops Margin | 43.87% |
| Profit Margin | 35.03% |
| RSI | 19.69 |
| BETA(β) | 0.44 |
| From 52week Low | -14.50% |
| From 52week High | -42.63% |
| EPS | 3.08 |
| EPS next Year | 3.97 |
| EPS next Qtr | 0.87 |
| EPS this Year | 18.60% |
| EPS next 5 Year | 11.00% |
| EPS past 5 Year | 16.48% |
| Sales past 5 Year | 14.25% |
| EPS Y/Y | 28.07% |
| Sales Y/Y | 27.73% |
| EPS Q/Q | 23.30% |
| Sales Q/Q | 22.49% |
| Sales Surprise | -2.85% |
| EPS Surprise | 0.19% |
| ATR(14) | 4.07 |
| Perf Week | -20.52% |
| Perf Month | -19.26% |
| Perf Quarter | -31.29% |
| Perf Year | -16.10% |
| Perf YTD | -17.83% |
| Target Price | 131.93 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer